Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-07
2008-10-14
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S058400
Reexamination Certificate
active
07435732
ABSTRACT:
This invention relates to crystalline polymorphs of (3S)-N-hydroxy4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide, and preparation and uses thereof.
REFERENCES:
patent: 6153757 (2000-11-01), Zook et al.
patent: 6225311 (2001-05-01), Levin et al.
patent: 6387901 (2002-05-01), Chupak et al.
patent: 7179911 (2007-02-01), Wang et al.
patent: WO 97/20824 (1997-06-01), None
patent: WO 98/34918 (1998-08-01), None
patent: WO 03/037852 (2003-05-01), None
Shire, M.G., et al., “TNF-alpha inhibitors and rheumatoid arthritis”,Exp. Opin. Ther. Patents, 1998, 8(5):531-544.
Grossman, J.M., et al., “Rheumatoid arthritis: current clinical and research directions”,J. Women's Health, , 1997, 6(6):627-638.
Isomaki, P. et al., “Pro- and anti-inflammatory cytokines in rheumatoid arthritis”,Ann. Med., 1997, 29(6):499-507.
Camussi, G., et al., “The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis”,Drugs, 1998, 55(5):613-620.
Van Assche, G., et al., “Anti-TNF agents in Crohn's disease”,Exp. Opin. Invesitig. Drugs, 2000, 9(1):103-11.
Rutgeerts, P. et al., “Novel Therapies for Crohn's Disease”,Drugs of Today, 2000, 36(Suppl. G.), 59-68.
Kreuger, G., et al., “Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis”,Archives of Dermatology, 2004, 140(2):218-25.
Kristensen, M., et al., “Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor”,Clin. Exp. Immunol., 1993, 94(2)354-62.
Lorenz, H.M., et al., “Perspective for TNF-alpha-targeting therapies”,Arthritis Res., 2002, 4(supple 3), S17-S24.
Wendling, D., et al., “Anti-TNF-alpha therapy in ankylosing spondylitis”,Exp. Opin. Pharmacotherapy, 2004, 5(7):1497-1507.
Mathison, J.C., et al., “Participation of Tumor Necrosis Factor in the Mediation of Gram Negative Bacterial Lipopolysaccharide-Induced Injury in Rabbits”,J. Clin. Invest., 1998, 81:1925-1937.
Miethke, et al., “T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor”,J. Exp. Med., 1992, 175:91-98.
Robertshaw, H.J., et al., Release of tumour necrosis factor alpha (TNFalpha) by TNFalpha cleaving enzyme (TACE) in response to septic stimuli in vitro,Br. J. Anaesth., 2005, 94(2):222-228.
Piguet, P.F., “Tumor necrosis factor/cachectin in an effector of skin and gut lesions of the acute phase of graft-vs.-host disease”,J. Exp. Med., 1987, 166:1280-1289.
Beutler, B., et al., Tumor necrosis, cachexia, shock, and inflammation: a common mediator,Ann. Rev. Biochem., 1988, 57:505-518.
Ksontini, R., et al., “Revisitng the role of Tumor Necrosis Factor alpha and the Response to Surgical Injury and Inflammation”,Arch. Surg., 1988, 133::558-567.
Packer, M., “Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?”,Circulation, 1995, 92(6):1379-1382.
Ferrari, R., et al., Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure,Circulation, 1995, (92(6):1479-1486.
Feldman, A.M., The role of tumor necrosis Factor in the pathophysiology of heart failure:,J. Am. Coll. Cardiol., 2003, 35:537.
Satoh, M.., et al., “Increased expression of tumor necrosis factor-alpha converting enzyme and tumor necrosis factor-alpha in peripheral blood mononuclear cells in patients with advanced congestive heart failure”,European J. Heart Failure, 2004, 6:869-875.
Gilles, S., et al., “Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers”,Cardiovascular Res., 2003, 60:608-616.
Moro, M.A., et al., “Expression and function of tumour necrosis factor-alpha-converting enzyme in the central nervous system”,Neurosignals, 2003, 12:53-58.
Colon, A.L., et al., Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis,Cytokine, 2001, 16(6):220-226.
Kirkegaard, T., et al., “Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells”,.Clin. Exp. Immunol., 2004, 135(1):146-53.
Hotamisligil, G.S., et al., “Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance”Science, 1993, 259:87-91.
Hotamisligil, G.S., et al., “Tumor Necrosis Factor alpha: A Key Component of the Obesity-Diabetes Link”,Diabetes, 1994, 43:1271-1276.
Morimoto, Y., et al., “KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production”,Life Sci., 1997, 61(8):795-803.
Trifilieff, A., et al., “Pharmacological profile of PKF242-484 and PKF241-66, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation”,Brit. J. Pharmacol., 2002, 135(7):1655-64.
Wang, X. et al., “Inhibitor of Tumor Necrosis Factor-alpha-Converting Enzyme by a Selective Antagonist Protects Brain from Focal Ischemic Injury in Rats”,Mol. Pharmacol. 2004, 65(4)896:890.
Wang, X., et al., Inhibition of Tumor Necrosis Factor-alpha Converting Enzyme by a Selective Small Molecular Antagonist Protects Brain from Thrombo-Embolic Ischemic Injury in Rat,Circulation, 2003, (Abstracts from Scientific Sessions - 17 Supp) IV-103.
Hallenbeck, J.M., “The many faces of tumor necrosis factor in stroke”,Nature Medicine, 2002, 8(12):1363-1368.
Meli, D.N., et al., “In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex”,J. Neuroimmunology, 2004, 151::6-11.
Nelson, A.R., et al., “Matrix metalloproteinases: biologic activity and clinical implications”,J. Clin. Oncol., 2000, 18(5):1135-1149.
Clements, J.M., et al., “Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor”,J. Neuroimmunol. 1997, 74:85-94.
Peterson, P.K., et al., “Human cytomegalovirus-stimulated peripheral blood mononuclear cells induce HIV-1 replication via a tumor necrosis factor-alpha-mediated mechanism”,J. Clin. Invest., 1992, 89(2):574-580.
Pallares-Trujillo, J., et al., “TNF and AIDS: two sides of the same coin?”,Med. Res. Reviews, 1995, 15(6):533-546.
Old, L. “Tumor necrosis factor (TNF)”,Science, 1985, 230(4726):630-632.
Rankin, E.C., et al., “The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.”,Br. J. Rheumatol., 1995, 34(4):334-342.
Pharmaprojects, 1996, Therapeutic Updates 17(Oct.) au197-M2Z.
McGeehan, G., et al., “TNF-alpha in Human Diseases”,Current Pharmaceutical Design, 1996, 2:662-667.
Remington's Pharmaceutical Sciences, 17thed., Ed. Alfonso R. Gennaro, Mack Publishing Co., Easton, Pa., 1985.
Sorbera, et al., “Prinomastat:oncolytic, matrix metalloprotase inhibitor”,Drugs of the Future, 2000,. 25(2): 150-158.
Shirokova, E. et al, “Novel Acyclic Nucelotides and Nucleoside 5'-Triphosphates Imitating 2',3'-Dideoxy-2'3'-didehydronucleotides:Synthesis and Biological Properties”, 1994, 37:3739-3748.
Akin Jean Marie
Deshmukh Subodh S.
Krishnan Lalitha
Larkin Peter John
Tadayon Abdolsamad
Habte Kahsay T
Pepper Hamilton LLP
Wyeth
LandOfFree
Crystalline polymorphs of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline polymorphs of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline polymorphs of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4000429